|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
KemPharm, Inc. Focuses on Advanced Pain Management Franchise
5/22/2012 9:55:50 AM
NORTH LIBERTY, Iowa, May 22, 2012 (GLOBE NEWSWIRE) -- KemPharm, Inc. ("KemPharm"), a clinical-stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, today provided an update on its business and development stage programs. The Company plans to leverage its deep pipeline of new chemical entities (NCEs) designed to improve the safety of opioid-based pain therapies by reducing the potential for drug abuse and diversion as well as reducing or eliminating the side effect of opioid-induced constipation (OIC). KemPharm is currently seeking a development and commercialization partner for its lead product, KP201, which is on track to file for FDA-approval in mid-2013.
|
|
|
|
|
|
|
|
|
|
|